Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

DSpace/Manakin Repository

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

Citable link to this page

 

 
Title: Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Author: Vernovsky, Kathy; Kuhlmann, Georgiana; Boisvert, Susan L; Stubbs, Hannah; McDermott, Ultan; Settleman, Jeffrey; Lynch, Thomas J; Dias-Santagata, Dora; Akhavanfard, Sara; David, Serena S; Kwak, Eunice Lee; Clark, Jeffrey William; Isakoff, Steven Jay; Sequist, Lecia VanDam; Engelman, Jeffrey Adam; Haber, Daniel Arie; Louis, David Neil; Ellisen, Leif William; Borger, Darrell R.; Iafrate, Anthony John

Note: Order does not necessarily reflect citation order of authors.

Citation: Dias-Santagata, Dora, Sara Akhavanfard, Serena S David, Kathy Vernovsky, Georgiana Kuhlmann, Susan L Boisvert, Hannah Stubbs, Ultan McDermott, Jeffrey Settleman, Eunice L Kwak, Jeffrey W Clark, Steven J Isakoff, Lecia V Sequist, Jeffrey A Engelman, Thomas J Lynch, Daniel A Haber, David N Louis, Leif W Ellisen, Darrell R Borger, and A John Iafrate. 2010. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine 2(5): 146-158.
Full Text & Related Files:
Abstract: Targeted cancer therapy requires the rapid and accurate identification of genetic abnormalities predictive of therapeutic response. We sought to develop a high-throughput genotyping platform that would allow prospective patient selection to the best available therapies, and that could readily and inexpensively be adopted by most clinical laboratories. We developed a highly sensitive multiplexed clinical assay that performs very well with nucleic acid derived from formalin fixation and paraffin embedding (FFPE) tissue, and tests for 120 previously described mutations in 13 cancer genes. Genetic profiling of 250 primary tumours was consistent with the documented oncogene mutational spectrum and identified rare events in some cancer types. The assay is currently being used for clinical testing of tumour samples and contributing to cancer patient management. This work therefore establishes a platform for real-time targeted genotyping that can be widely adopted. We expect that efforts like this one will play an increasingly important role in cancer management.
Published Version: doi:10.1002/emmm.201000070
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377316/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436341
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters